MK-677 vs Semaglutide
Well Studied vs FDA Approved
monitor Mechanism-based · 47% Both MK-677 and Semaglutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
MK-677 Semaglutide
Weight 624.77 Da 4,113.64 Da
Half-life ~24 hours ~7 days (168 hours)
Chain — 31 amino acids
Type Non-peptide ghrelin receptor agonist GLP-1 receptor agonist
Key Benefits
MK-677
01 97% increase in 24-hour growth hormone secretion
02 40-72% elevation in IGF-1 levels
03 Enhanced sleep quality with improved REM patterns
04 Preferential lean tissue gains of 1.1-2.7kg over 8-12 months
05 15% basal metabolic rate increase within 2 weeks
06 Oral administration (no injections required)
Semaglutide
01 15-20% average body weight reduction
02 Established cardiovascular protection
03 Convenient once-weekly dosing options
04 Comprehensive safety data from extensive trials
05 Flexible injectable and oral formulations
Dosing Protocols
MK-677
Start 12.5mg daily, increase to 25mg based on tolerance / Once daily, preferably at bedtime on empty stomach
Semaglutide
0.25mg starting, titrate to 1-2.4mg weekly / Once weekly (same day each week)
Weight Loss Initiation 0.25mg Weekly x 4 weeks, then increase
Weight Loss Maintenance 2.4mg Weekly (after 16-week titration)
Diabetes Management 0.5-1mg Weekly
Cardiovascular Protection 0.5-1mg Weekly
Tolerability-Based 0.25-2.4mg Weekly (individualized)
Side Effects
MK-677
Appetite stimulation (>50% of users)
Water retention (30-40%)
Lethargy (20-30%)
Fasting glucose elevation (5-15mg/dL)
Note on testosterone suppression: at doses up to 20 mg daily, MK-677 is unlikely to cause significant testosterone suppression on its own. Above 20 mg daily, the likelihood of suppression and other side effects (insulin resistance, water retention, lethargy) increases. The case report documenting 85.7% testosterone suppression involved co-administration with LGD-4033, a SARM known to be profoundly suppressive, making the SARM the likely primary driver of that suppression.
Semaglutide
Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Contraindications
Heart disease or congestive heart failure
Diabetes or pre-diabetes
Active cancer
Severe cardiovascular disease
Pregnancy or breastfeeding
Personal or family history of medullary thyroid cancer
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy or breastfeeding
History of pancreatitis
Research Evidence
MK-677 Semaglutide
Status Well Studied FDA Approved
References 7 studies 9 studies
Latest July 2024 2025-06
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.